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Background/Hypothesis: Adhesive capsulitis of the shoulder results in pain and restricted
movement of the glenohumeral joint. Hypothesis: There would be a difference in active range of
movement in the affected shoulder of patients with adhesive capsulitis after receiving a series of
injections of collagenase Clostridium histolyticum (CCH) compared to placebo.
Methods: This study reports the results from a single site that was part of a 321-participant,
multicenter, double-blind, prospective parallel-group, randomized controlled clinical trial.
Inclusion criteria: over 18 years of age, unilateral idiopathic adhesive capsulitis for >3
months, but <12 months. Exclusion criteria: recent physical therapy, injections, subacromial
impingement, calcific tendonitis or glenohumeral joint arthritis in the affected shoulder.
Subjects were randomized 3:1 to receive CCH 0.58 mg or placebo under ultrasound
guidance. Injections were on days 1, 22, and 43. The primary outcome measure was a
functional assessment of active range of movement.
Results: Overall, 37 patients were screened, 26 subjects were excluded, and 11 subjects
were randomly assigned to the treatment group (n=9) or the control group (n=2). Both
control and treatment groups showed improvement in ROM between baseline and day 95.
In the treatment group, AROM improved from the baseline of 272.89° (SD 86.25) to 462.11°
(SD 96.89) and the control group from 246.00° (SD 5.66) to 451.50° (SD 50.20) at day 95
with no statistical difference between groups p=0.78. Site data were in line with the whole
study findings. Treatment-related adverse events at the injection site, including haematoma
(bruising) and localised pain and swelling, were common.
Conclusion: Although the participants showed improvement in function, statistical signifi-
cance was neither reached in the site nor the overall study cohort. Given the adverse events
and the potential risks of the procedure, we would not recommend this drug for the treatment
of adhesive capsulitis of the shoulder.
Level of Evidence: 2, cohort from one site of RCT.
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Plain Language Summary
Adhesive capsulitis is a condition of the shoulder joint which frequently results in a painful
loss of movement. It has been difficult to treat and may last for many years. This study tested
a new drug (which has been used in Dupuytren's contractures of the hand before) to see
whether it could improve the movement in the affected shoulder of patients with adhesive
capsulitis. The results showed improvement in both the patients who received the new drug
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as well as those who had a placebo injection and shoulder
exercises. It also showed substantial side effects at the shoulder
of bruising. The authors feel they could not recommend the drug
for the treatment of this condition.
Introduction
Background
Adhesive capsulitis (AC) or frozen shoulder is a muscu-
loskeletal condition characterized by pain and restricted
movement of the glenohumeral joint. Its reported inci-
dence is 3–5% in the general population.8
Whilst it has been described as a condition of unknown
aetiology, there are several risk factors described for adhe-
sive capsulitis. These include female sex, age over 40
years, prolonged immobilisation of the shoulder, diabetes
mellitus, thyroid disease, stroke, myocardial infarction,
and autoimmune disease.10 The natural history of primary
adhesive capsulitis is characterised by a gradual onset and
progression of symptoms. Secondary adhesive capsulitis is
generally caused by trauma, surgery or subsequent immo-
bilisation, and the symptoms usually present soon after the
traumatic incident.8
The diagnosis is made clinically, with symptoms of
pain lying on the affected side and signs of restricted
external rotation of the shoulder.12
Magnetic resonance imaging (MRI) scans demonstrat-
ing thickened synovium or capsule, adhesions within the
subacromial or subdeltoid bursa, adhesions related to the
long head biceps tendon or obliteration of the axillary fold
secondary to adhesions are indicative of frozen shoulder.8
A high T2 intensity signal on MRI scan of the inferior
glenohumeral ligament is also indicative of AC.10
The pathophysiology of AC is postulated to be an
immunological response to an inflammatory synovitis
which results in fibrosis of the capsule.12 Manske,
Prohaska8 described three distinct clinical phases in the
progression of AC. The first termed the “freezing” (the
inflammatory) stage is the most painful. This stage is
characterised by acute synovitis of the glenohumeral
joint, with a progressive loss of both active and passive
range of movement (ROM) as the condition progresses.
The second, “frozen” stage is characterised by restricted
external rotation of the glenohumeral joint, with ongoing
shoulder pain. The final, “thawing” stage is characterised
by a gradual reduction in pain and some return of shoulder
mobility.
Despite AC having a “benign prognosis” (most patients
regain at least partial ROM) even with no medical
intervention, the long-lasting and profoundly debilitating
course of the disease (up to 3 years) and the limited
recovery of the ROM have motivated the pursuit of a
myriad of treatment alternatives. Treatments are aimed at
pain relief and restoration of ROM. Non-operative treat-
ments include oral non-steroidal anti-inflammatory medi-
cations or corticosteroids, intra-articular glucocorticoid
injections and capsular distention injections. Non-steroidal
anti-inflammatory drugs have been shown to reduce pain
in the freezing stage, although the effect is not sustained in
the longer term.8 Intra-articular injections of glucocorti-
coids provide short-term relief and are typically performed
as a sub-acromial or glenohumeral injection.8 Capsular
distention injections or hydro-dilatation procedures
involve stretching the capsule to its limits by injecting
local anaesthetics, saline solution and glucocorticoids
into the affected joint.7 Capsular distention has been
shown to increase ROM, with the effect lasting over a
year.15 Physiotherapy, whilst playing an important role
post-operatively, has shown to offer little benefit when
used as the sole treatment for AC.2 Physiotherapy is best
implemented once patients are beyond the painful freezing
stage.6 Repeated nerve blocks of the suprascapular nerve
have been shown to improve the quality of life and func-
tional capacity of some patients.4
Surgical interventions are considered following failed
conservative treatment. Manipulation under anaesthetic
(MUA) or arthroscopic capsulotomy improves ROM and
is enhanced by post-operative physiotherapy.5
As many of these treatments improve pain but not
necessarily ROM, or offer a limited benefit in terms of
ROM, there is a need to consider conservative treatments
that may impact on both pain and function in the long
term. A previous randomised controlled pilot study in 60
participants with AC had demonstrated that 53 participants
improved their ROM after a series of collagenase
Clostridium histolyticum (AA4500) injections.1
Collagenase Clostridium histolyticum (CCH) is a combi-
nation of two collagenases (CCH-I and CCH-II) and is an
FDA-approved enzymatic injection treatment for
Dupuytren’s contracture. It was postulated that the effects
of CCH seen in Dupuytren’s contracture may be similar if
used for management of AC, providing in this case a
clinically significant increase in the ROM.
This report describes the results from one site (includ-
ing 11 participants) from a multi-centre trial of 321 parti-
cipants looking at the effectiveness of a series of CCH
injections for AC.
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Objective
There would be a difference in active range of movement
in the affected shoulder of patients with adhesive capsulitis
after receiving a series of injection of CCH when com-
pared to a placebo.
Methods
Trial Design
This study reports the results from a single site (Richmond,
Australia) that was part of a multicenter double-blind pro-
spective parallel-group randomised controlled clinical trial.
The trial was registered with www.ClinicalTrials.gov
NCT02006719 and received site ethics approval from
Bellberry 2013–10-535. The subjects, Clinical Investigator
(treating physician), and investigators examining the data
were blinded to the treatment allocation and results until the
end of the study following statistical analysis. Informed
consent was obtained from participants and CONSORT
guidelines followed. No changes were made to the trial
design after commencement. The protocol is available in
the supplementary material.
Subject Selection
Participants were enrolled in the study from June 2014 –
September 2014, if they were over 18 years of age and
presented with symptoms of unilateral idiopathic adhesive
capsulitis for at least 3 months, but not longer than 12
months. Inclusion criteria stated that participants were in
the frozen or adhesive stage of the condition, as deter-
mined by the investigator. The affected shoulder must
have had a restricted active range of total active movement
(AROM) of at least 60° compared to the contralateral
shoulder. Deficits in AROM had to be present in at least
one of the following planes of movement: forward flexion,
abduction, external rotation, and/or internal rotation.
The main exclusion criteria were physical therapy or
acupuncture within 2 weeks before the first injection of the
study drug; intra-articular or intra-bursal injections of
lidocaine or sodium hyaluronate, suprascapular nerve
blocks or glenohumeral distention arthrography within 3
months before the screening visit. Participants were also
excluded if they presented with active subacromial impin-
gement, calcified tendonitis or glenohumeral joint arthritis
in the affected shoulder.
Participation was voluntary, and an informed consent
agreement, approved by the Independent Ethics Committee,
was signed prior to participation.
Randomization
Following screening and conformation of eligibility to
participate in the study, patients were randomised 3:1 to
receive CCH 0.58 mg or placebo. A central randomisation
scheme with an interactive web response system was used
by the trial coordinator.
Interventions
Participants were injected with either the CCH injection
or a placebo (saline solution) under ultrasound guidance.
Participants received up to three injections of study drug
on days 1, 22, and 43 of the study. Each injection was
separated by a minimum of 21 days and followed by a
specified home exercise program which was demon-
strated to the participants. The components of the study
drug were: 0.9mg of collagenase Clostridium histolyti-
cum, 0.5 mg of hydrochloric acid, 18.5 mg of sucrose and
1.1 mg of tromethamine diluted with calcium and sodium
chloride solution. 1 mL of the product was injected ante-
riorly under ultrasound guidance using a 22 g Sprotte
needle.
Both groups were given the same unsupervised home
exercise regime with directed activity modification post-
treatment without physiotherapist consultation.
Outcomes
The primary outcome measure was a functional assess-
ment of active range of movement (AROM) and passive
range of movement (PROM). Movements assessed were
shoulder flexion, extension, external rotation, and internal
rotation. The AROM used as our primary outcome mea-
sure was assessed by the treating Physician at screening,
day 1, day 8, day 22, day 29, day 43, day 50, day 64, and
day 95 (end of study). Compliance with the home exercise
regime was recorded.
Sample Size
This study looks at the data set from a single site involving
11 participants, as part of a larger, multi-centre trial of 321
participants.
Blinding
This was a double-blinded study in which the investigator,
patient, and other study personnel involved in the evalua-
tion were blinded. The trial drug and placebo were iden-
tical in appearance, labelling and colour.
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Statistical Methods
Statistical analysis was conducted on an intention-to-treat
basis (ITT) using STATA version 13 (Stata Corp. 2013
Stata Statistical Software: Release 13. College Station,
TX: Stata Corp LP). Treatment comparisons were based
on the change in AROM on day 95, with significance at
P<0.05. Standard t-tests with equal variance were per-
formed on day 95.
Results
Patient Study and Follow-Up
During the recruitment period, a total of 37 patients were
assessed. 26 subjects were excluded, leaving 11 subjects
who randomly assigned to the treatment group (n=9) or the
control group (n=2) and analysed by intention to treat.
Figure 1 shows the flow of patients in the trial, none lost
to follow-up. Table 1 shows the demographic data of the
patients. The groups showed similar demographics in rela-
tion to age, body mass index (BMI), height, and weight.
Primary Outcome
Table 2 shows the mean range of motion (ROM) in total
active range of movement (AROM), active external rota-
tion (AER), and active forward flexion (AFF) for both the
treatment and control group at baseline (day 0), 43 days,
and 95 days.
Figure 1 Consort flow diagram.
Abbreviation: n, number.
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The mean AFF at baseline for the treatment group was
110.33° (SD 21.68), compared to the control group mean
of 117.00° (SD 5). Both the control and treatment groups
showed improvement in AFF over the course of the study.
The means at day 43 for the treatment and control groups,
respectively, were 161.33° (SD 20.83) and 154.00°. At day
95, the treatment group had a mean AFF of 167.33° (SD
21.12), while the control group had a mean of 173.50° (SD
1.50) p=0.95.
The mean AER at baseline for the treatment and con-
trol groups, respectively, were 43.56° (SD 25.62) and
26.00° (SD 1.41). At day 43, there was a difference in
AER control 37° (SD-) and treated 77° (SD 26) p=0.46 but
this was not sustained at day 95. The AER for the treat-
ment group improved from 43.56° (SD 25.62) at baseline
to 84.78° (SD 24.85) at day 95 compared to the control
group 26.00° (SD 1.41) at baseline and 86.50° (SD 6.36)
at day 95.
The mean AROM at baseline for the treatment and
control groups, respectively, were 272.89° (SD 86.25)
and 246.00° (SD 5.66). At 43 days there was a difference
in AROM with control group 300° (SD-) and treated group
430° (SD 94). This was not sustained at 95 days with
treated group 462.11° (SD 96.89) and the control group
451.50° (SD 50.20) at 95 days, p=0.78.
Adverse Events
As previously reported1 all participants who received
CCH had treatment-related adverse events at the injec-
tion site, including haematoma (bruising) and localised
pain and swelling. Table 3 shows the adverse events.
Bruising was seen in 100% of the treated group and
none of the control group. Of note was the extent of the
bruising in 66%which extended from the sternum and
involved the whole of the breast to the midline and the
upper arm to the elbow. All participants had pain post-
procedure – the difference was in the length of time
analgesia was required with 88% of the treated group
using analgesia including opioids beyond 24 hrs (Mean
78 hrs (24–288)) and none of the control group requir-
ing analgesia beyond 12 hrs. There were no serious
adverse events related to the study drug.
Table 1 Demographic Data of the Treatment and Control Groups
Characteristics Treatment
Group (n= 9)
Control
Group (n=2)
Age, years mean, (range) 46.22 (32–55) 56 (49–63)
Sex n, (%)
Male 1 (11.11) 0 (0)
Female 8 (88.89) 2 (100)
BMI, kg/m2 mean 25.71 25.29
Height, cm mean (SD) 170.19 (8.69) 165.3 (3.25)
Weight, kg mean (SD) 74.31 (9.62) 68.85 (1.20)
Abbreviations: n, number; SD, standard deviation; BMI, body mass index.
Table 3 Adverse Events
Description Control Group
N (%)
Treatment
Group N (%)
Bruising 9 (100%)
Major to midline or
elbow
6 (66%)
Minor localised 3 (33%)
Nil 2 (100%) 0 (0%)
Swelling localised – 4 (44%)
Pins and needles or
numbness
– 2 (22%)
Pain 2 (100%) 8 (88%)
Opioid analgesia 2 (100%) 8 (88%)
Other analgesia eg
acetaminophen
– 5 (55%)
Duration of analgesia in
hours
2 (100%) 8 (88%)
N (%) mean hours (Range
in hours)
6 hours (4–8) 78 hours (24–288)
Abbreviations: N, number; %, percentage of total in group.
Table 2 Primary Outcome Measures at Baseline, 43 Days, and 95
Days
Time Baseline 43 Days 95 Days
AROM, degrees mean (SD)
Treatment
group (n=9)
272.89 (86.25) 430.78 (94.04) 462.11 (96.89)
Control group
(n=2)
246.00 (5.66) 300.00 (-) 451.50 (50.20)
AFF, degrees mean (SD)
Treatment
group
110.33 (21.68) 161.33 (20.83) 167.33 (21.15)
Control group 117.00 (5) 154.00 (-) 173.50 (1.50)
AER, degrees mean (SD)
Treatment
group
43.56 (25.62) 77.00 (26.09) 84.78 (24.85)
Control group 26.00 (1.41) 37.00 (-) 86.50 (6.36)
Abbreviations: AROM, total active range of movement; AFF, active forward
flexion; AER, active external rotation; SD, standard deviation.
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Discussion
This study compared the change in ROM in subjects with
adhesive capsulitis of the shoulder treated with CCH com-
pared to a placebo. The data showed no significant differ-
ence between the control and treatment groups. Of
importance, the site data reflected the overall study data
which also showed improvement in function but no statis-
tical significance between the groups.11 The function of
both the control and treatment groups improved over the
course of the study, suggesting that the home exercise
program, completed by both groups, may improve func-
tional outcomes in adhesive capsulitis of the shoulder. The
natural history of the condition may have accounted for
the improvement.8
The authors felt that it was important to report the
findings of this study, even though there was a negative
outcome. With any new treatment, it is important to assess
effectiveness, but it is also important to consider whether
there are potential harms associated with the new treat-
ment. It is important to note that 100% of participants who
received the CCH had substantial bruising at the injection
site. This extended in some people from the sternum right
across the chest wall and down the arm to the elbow.
Whilst it is temporary, it is much more extensive than
would have been expected from any other injection such
as hyaluronic acid or glucocorticoid. This may be particu-
larly important if the injections became more widely used
particularly in a population who may be under anticoagu-
lants and be expected to bruise more easily.
Many treatment strategies have been studied. Classical
needle acupuncture has been shown to reduce shoulder
pain scores, but only relieves the pain symptoms in the
short term.14 Similarly, trigger point dry needling has
demonstrated transitory improvements in range of motion
and other functional outcomes, however, this requires
multiple visits over a 6-week time-frame.3 Transcatheter
arterial embolization has been trialled as a treatment after
patients have shown resistance to other conservative treat-
ments, and has been shown to reduce pain.9 Extracorporeal
shockwave therapy has also been trialled as a treatment in
diabetic patients with adhesive capsulitis of the shoulder,
demonstrating an improvement in functional outcomes
following treatment.13
A recent prospective randomized study compared
the efficacy of 3 injection methods, intra-articular
injection, subacromial injection, and hydrodilatation
(HD), in the treatment of primary frozen shoulder.
The authors found benefit from the three with no dif-
ference at 6 months.16
The injection technique used required the use of a blunt
needle (which could not penetrate the capsule of the gle-
nohumeral joint) and the use of ultrasound guidance for
accurate needle placement extra-articularly. Administering
the intra-articular injection, there is a risk of damaging
other structures within the joint, which may lead to other
adverse events for the patient.
Taking into consideration these adverse events, and the
lack of statistical significance in the benefit, we cannot
recommend this treatment for patients with adhesive cap-
sulitis of the shoulder.
The significant limitation of this study is the small
sample size but this site report from the 321-patient
study had similar results to that of the overall study.
Conclusion
Although the data in this study showed improvement in
function over the course of the study, statistical signifi-
cance was not reached in the site nor the overall study
cohort. Given the adverse events and the potential risk in
the procedure, we would not recommend this drug for the
treatment of adhesive capsulitis of the shoulder unless
further studies demonstrated more significant outcomes.
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